A Trial Investigating the Pharmacokinetic and Safety of NN1250 [insulin degludec] in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function.
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Insulin degludec (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 29 Jun 2012 Actual patient number changed from 16 to 32 as reported by ClinicalTrials.gov.
- 27 May 2010 Actual patient number (16) added as reported by ClinicalTrials.gov.
- 27 May 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History